Document is current
Any future updates will be listed below
-
Authors
Yang, Xing
Huang, Ryan
Fang, Meng https://orcid.org/0009-0000-0122-416X
He, Yubo
Xie, Jingjing
Liu, Xiaoye
Zhang, Chengcheng
Lou, Qi
Deng, Mi
Xiong, Wei
Lewis, Cheryl
Sadek, Zade
Gupta, Ankit https://orcid.org/0000-0001-5295-180X
Chen, Lianqi https://orcid.org/0000-0002-0392-0633
Zhang, Xuewu https://orcid.org/0000-0002-3634-6711
Guo, Lei
Xu, Lin https://orcid.org/0000-0001-5815-4457
Zhang, Ningyan https://orcid.org/0000-0002-4348-2180
An, Zhiqiang https://orcid.org/0000-0001-9309-2335
Zhang, Cheng Cheng https://orcid.org/0000-0003-4763-3887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA248736)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA263079)
Cancer Prevention and Research Institute of Texas (RP220032)
Cancer Prevention and Research Institute of Texas (RP15150551)
Cancer Prevention and Research Institute of Texas (RP190561)
Lung Cancer SPORE Development Research Program Immune-Onc Therapeutics, Inc
the CPRIT training grant
U.S. Department of Health & Human Services | National Institutes of Health (P30CA142543)
U.S. Department of Health & Human Services | National Institutes of Health (R35GM130289)
Welch Foundation (I-1702)
Welch Foundation (AU-0042-20030616)
- License Information
-
More Information
Article History
Received: 19 December 2024
Accepted: 18 June 2025
First Online: 24 July 2025
Competing interests
: Authors R.H., Y.H., M.D., W.X., N.Z., Z.A. and C.C.Z. are listed as inventors on relevant patent applications that were exclusively licensed to Immune-Onc Therapeutics by the Board of Regents of the University of Texas System. Authors M.D., Z.A., N.Z. and C.C.Z. hold equity in and had Sponsored Research Agreements with Immune-Onc Therapeutics. The University of Texas has a financial interest in Immune-Onc in the form of equity and licensing. The other authors declare no competing interests.
